Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World
Authors:
- 19 March 2022
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (8) , e685-e690
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneBlood Cancer Journal, 2019
- Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geographyCancer Epidemiology, 2019
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeBlood Cancer Journal, 2018
- Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2018
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisLeukemia, 2018
- Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North IndiaIndian Journal of Hematology and Blood Transfusion, 2017
- Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsLeukemia, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- Early mortality in multiple myelomaLeukemia, 2015